10-Q Filing

SOLENO THERAPEUTICS INC CIK: 1484565 Q3 2022

Filing Information

Form Type	10-Q
Accession Number	`0000950170-22-023838`
Period End Date	20220930
Filing Date	20221109
Fiscal Year	2022
Fiscal Period	Q3
XBRL Instance	slno-20220930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 62 Income Statement 64 Cash Flow Statement 53 Stockholders Equity 40

Balance Sheet 62 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.32M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	8.16M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.32M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	8.16M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$19.75M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$21.30M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$821.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.12M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$22.42M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$20.57M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$33.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$23.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$206.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$421.00K	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$600.00K	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$12.64M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$11.18M	USD	Point-in-time
Other long-term assets	`OtherAssetsNoncurrent`	$40.00K	USD	Point-in-time
Total assets	`Assets`	$31.98M	USD	Point-in-time
Total assets	`Assets`	$35.55M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.25M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.32M	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$728.00K	USD	Point-in-time
Accrued compensation	`EmployeeRelatedLiabilitiesCurrent`	$1.28M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$2.83M	USD	Point-in-time
Accrued clinical trial site costs	`AccruedClinicalTrialCostsCurrent`	$3.42M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$282.00K	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityCurrent`	$239.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$671.00K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$323.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$8.01M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$7.34M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$9.55M	USD	Point-in-time
Contingent liability for Essentialis purchase price	`AssetAcquisitionContingentConsiderationLiabilityNoncurrent`	$9.44M	USD	Point-in-time
Long-term lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$175.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$17.76M	USD	Point-in-time
Total liabilities	`Liabilities`	$16.78M	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 6)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 8,159,382 and 5,324,287 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.	`CommonStockValue`	$8.00K	USD	Point-in-time
Common stock, $0.001 par value, 100,000,000 shares authorized, 8,159,382 and 5,324,287 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively.	`CommonStockValue`	$80.00K	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$247.13M	USD	Point-in-time
Additional paid-in-capital	`AdditionalPaidInCapitalCommonStock`	$231.07M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-231.94M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-213.35M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.00K	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$15.20M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$37.57M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$26.46M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$20.31M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$20.20M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$45.55M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$27.44M	USD	Point-in-time
Total stockholders equity	`StockholdersEquity`	$17.79M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$31.98M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$35.55M	USD	Point-in-time

Income Statement 64 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$11.46M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.97M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$17.72M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.77M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$7.44M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.77M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$8.21M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.33M	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$132.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$2.60M	USD	3 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$551.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-110.00K	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$28.53M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$6.24M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$18.79M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$8.29M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-8.29M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-28.53M	USD	3 Qtrs
Operating loss	`OperatingIncomeLoss`	$-6.24M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-18.79M	USD	3 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-369.00K	USD	3 Qtrs
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-112.00K	USD	1 Quarter
Change in fair value of warrants liabilities	`FairValueAdjustmentOfWarrants`	$-31.00K	USD	3 Qtrs
Interest income	`OtherNonoperatingIncomeExpense`	$101.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$34.00K	USD	1 Quarter
Interest income	`OtherNonoperatingIncomeExpense`	$175.00K	USD	3 Qtrs
Interest income	`OtherNonoperatingIncomeExpense`	$76.00K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$445.00K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$103.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$206.00K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$146.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.14M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-18.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.99M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.13M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.95M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-28.08M	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-6.13M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-18.58M	USD	3 Qtrs
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-8.14M	USD	1 Quarter
Total comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-28.08M	USD	3 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-0.76	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-5.28	USD	3 Qtrs
Net loss per common share basic	`EarningsPerShareBasic`	$-1.53	USD	1 Quarter
Net loss per common share basic	`EarningsPerShareBasic`	$-2.60	USD	3 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-2.60	USD	3 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-5.28	USD	3 Qtrs
Net loss per common share diluted	`EarningsPerShareDiluted`	$-0.76	USD	1 Quarter
Net loss per common share diluted	`EarningsPerShareDiluted`	$-1.53	USD	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	5.32M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	7.16M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	5.32M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate basic net loss per common share	`WeightedAverageNumberOfSharesOutstandingBasic`	8.09M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	8.09M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	7.16M	shares	3 Qtrs
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	5.32M	shares	1 Quarter
Weighted-average common shares outstanding used to calculate diluted net loss per common share	`WeightedAverageNumberOfDilutedSharesOutstanding`	5.32M	shares	3 Qtrs

Cash Flow Statement 53 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-18.58M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-28.08M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.48M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$1.47M	USD	3 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$215.00K	USD	3 Qtrs
Non-cash lease expense	`NoncashLeaseExpense`	$220.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$1.90M	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$2.86M	USD	3 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-369.00K	USD	3 Qtrs
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-2.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-112.00K	USD	1 Quarter
Change in fair value of stock warrants	`FairValueAdjustmentOfWarrants`	$-31.00K	USD	3 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$132.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$2.60M	USD	3 Qtrs
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$551.00K	USD	1 Quarter
Change in fair value of contingent consideration	`AssetAcquisitionContingentConsiderationChangeInFairValue`	$-110.00K	USD	3 Qtrs
Other non-cash reconciling items	`OtherNonCashReconcilingItems`	$-2.00K	USD	3 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-317.00K	USD	3 Qtrs
Prepaid expenses, other current assets and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-337.00K	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$40.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-930.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-369.00K	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-196.00K	USD	3 Qtrs
Accrued compensation	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$554.00K	USD	3 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$196.00K	USD	3 Qtrs
Accrued clinical trial site costs	`IncreaseDecreaseInAccruedClinicalTrialSiteCosts`	$-594.00K	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-218.00K	USD	3 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$-156.00K	USD	3 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$299.00K	USD	3 Qtrs
Other liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$348.00K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-20.91M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-15.64M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$9.00K	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$7.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-9.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-7.00K	USD	3 Qtrs
Proceeds from sale of common stock and pre-funded warrants, net of costs	`ProceedsFromSaleOfCommonStockAndPreFundedWarrantsNetOfCosts`	$14.11M	USD	3 Qtrs
Tax withholding payments for net share-settled equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	3 Qtrs
Tax withholding payments for net share-settled equity awards	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$120.00K	USD	3 Qtrs
Principal paid on finance lease liabilities	`FinanceLeasePrincipalPayments`	$3.00K	USD	3 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-123.00K	USD	3 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$14.09M	USD	3 Qtrs
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-21.04M	USD	3 Qtrs
Net decrease in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.55M	USD	3 Qtrs
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$28.18M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$49.22M	USD	Point-in-time
Cash and cash equivalents, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.75M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.30M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$28.18M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$49.22M	USD	Point-in-time
Cash and cash equivalents, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$19.75M	USD	Point-in-time
Right-of-use assets obtained in exchange for operating lease obligations	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$581.00K	USD	3 Qtrs

Stockholders Equity 40 line items

Line Item	Tag	Value	Unit	Period
Less transaction costs	`PaymentsOfStockIssuanceCosts`	$1.03M	USD	1 Quarter
Balances at beginning	`StockholdersEquity`	$15.20M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$37.57M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$20.20M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$45.55M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$27.44M	USD	Point-in-time
Balances at beginning	`StockholdersEquity`	$17.79M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$683.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$857.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$571.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$464.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$906.00K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$1.09M	USD	1 Quarter
Issuance of restricted stock units under equity incentive plan	`IssuanceOfRestrictedStockUnitsValueAndOptionExercisesUnderEquityIncentivePlan`	$180.00K	USD	1 Quarter
Tax withholding payments for net share-settled equity awards	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$16.00K	USD	1 Quarter
Tax withholding payments for net share-settled equity awards	`AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation`	$120.00K	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$342.00K	USD	1 Quarter
Sale of common stock\pre-funded warrants in public offering, net of costs	`StockIssuedDuringPeriodValueNewIssues`	$13.77M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.14M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-18.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-5.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-10.99M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.13M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-8.95M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-6.72M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-28.08M	USD	3 Qtrs
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.00K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.00K	USD	3 Qtrs
Balances at ending	`StockholdersEquity`	$15.20M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$37.57M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$26.46M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$20.31M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$20.20M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$45.55M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$27.44M	USD	Point-in-time
Balances at ending	`StockholdersEquity`	$17.79M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.